{"entity":{"id":"nct07499362","kind":"trial","name":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","aka":[],"tldr":"A phase 2 trial of Pimicotinib in tenosynovial giant cell tumour, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, now recruiting.","summary":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) is a phase 2 interventional study registered as NCT07499362 by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, with 20 participants planned, started 2026-03-26 and due to reach its primary completion in 2029-11-22. Interventions recorded: Pimicotinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07499362","url":"https://clinicaltrials.gov/study/NCT07499362"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tenosynovial-giant-cell-tumour"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07499362","phase":"2","setting":"Phase 2, Single-arm Study to Investigate the Tolerability, Pharmacokinetics, Efficacy, and Safety of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","enrolled":20,"outcomes":[]},"route":"/trials/nct07499362/","neighbours":{"cancer":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/"}],"drug":[{"id":"pimicotinib","kind":"drug","name":"Pimicotinib","route":"/drugs/pimicotinib/"}]}}